These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 30806848)

  • 1. Axitinib pharmacologic therapeutic monitoring reveals severe under-exposure despite titration in patients with metastatic renal cell carcinoma.
    Beinse G; Hulin A; Rousseau B
    Invest New Drugs; 2019 Dec; 37(6):1289-1291. PubMed ID: 30806848
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Absorption of the orally active multikinase inhibitor axitinib as a therapeutic index to guide dose titration in metastatic renal cell carcinoma.
    Fukudo M; Tamaki G; Azumi M; Kakizaki H; Matsumoto S; Tasaki Y
    Invest New Drugs; 2021 Apr; 39(2):595-604. PubMed ID: 33098047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic Drug Monitoring for Tyrosine Kinase Inhibitors in Metastatic Renal Cell Carcinoma.
    Henriksen JN; Andersen CU; Fristrup N
    Clin Genitourin Cancer; 2024 Jun; 22(3):102064. PubMed ID: 38555681
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Axitinib dose titration: analyses of exposure, blood pressure and clinical response from a randomized phase II study in metastatic renal cell carcinoma.
    Rini BI; Melichar B; Fishman MN; Oya M; Pithavala YK; Chen Y; Bair AH; Grünwald V
    Ann Oncol; 2015 Jul; 26(7):1372-7. PubMed ID: 25701454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Axitinib in metastatic renal cell carcinoma: results of a pharmacokinetic and pharmacodynamic analysis.
    Rini BI; Garrett M; Poland B; Dutcher JP; Rixe O; Wilding G; Stadler WM; Pithavala YK; Kim S; Tarazi J; Motzer RJ
    J Clin Pharmacol; 2013 May; 53(5):491-504. PubMed ID: 23553560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contribution of UGT1A1 genetic polymorphisms related to axitinib pharmacokinetics to safety and efficacy in patients with renal cell carcinoma.
    Igarashi R; Inoue T; Fujiyama N; Tsuchiya N; Numakura K; Kagaya H; Saito M; Narita S; Satoh S; Niioka T; Miura M; Habuchi T
    Med Oncol; 2018 Mar; 35(4):51. PubMed ID: 29524031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of Axitinib After Nivolumab Failure in Metastatic Renal Cell Carcinoma.
    Ishihara H; Takagi T; Kondo T; Fukuda H; Tachibana H; Yoshida K; Iizuka J; Okumi M; Ishida H; Tanabe K
    In Vivo; 2020; 34(3):1541-1546. PubMed ID: 32354960
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncological outcomes of a multicenter cohort treated with axitinib for metastatic renal cell carcinoma.
    Osawa T; Kojima T; Hara T; Sugimoto M; Eto M; Takeuchi A; Minami K; Nakai Y; Ueda K; Ozawa M; Uemura M; Miyauchi Y; Ohba K; Suzuki T; Anai S; Shindo T; Kusakabe N; Tamura K; Komiyama M; Goto T; Yokomizo A; Kohei N; Kashiwagi A; Murakami M; Sazuka T; Yasumoto H; Iwamoto H; Mitsuzuka K; Morooka D; Shimazui T; Yamamoto Y; Ikeshiro S; Nakagomi H; Morita K; Tomida R; Mochizuki T; Inoue T; Kitamura H; Yamada S; Ito YM; Murai S; Nishiyama H; Shinohara N;
    Cancer Sci; 2020 Jul; 111(7):2460-2471. PubMed ID: 32402135
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Individualized Dosing of Axitinib Based on First-Dose Area Under the Concentration-Time Curve for Metastatic Renal-Cell Carcinoma.
    Miura Y; Imamura CK; Uchino K; Kishida T; Matsubara N; Shinojima T; Kondo K; Hongo F; Yoshimura K; Tanigawara Y; Takano T
    Clin Genitourin Cancer; 2019 Feb; 17(1):e1-e11. PubMed ID: 30529389
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patients with metastatic renal cell carcinoma who benefit from axitinib dose titration: analysis from a randomised, double-blind phase II study.
    Tomita Y; Uemura H; Oya M; Shinohara N; Habuchi T; Fujii Y; Kamei Y; Umeyama Y; Bair AH; Rini BI
    BMC Cancer; 2019 Jan; 19(1):17. PubMed ID: 30616534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An Open Label Phase Ib Dose Escalation Study of TRC105 (Anti-Endoglin Antibody) with Axitinib in Patients with Metastatic Renal Cell Carcinoma.
    Choueiri TK; Michaelson MD; Posadas EM; Sonpavde GP; McDermott DF; Nixon AB; Liu Y; Yuan Z; Seon BK; Walsh M; Jivani MA; Adams BJ; Theuer CP
    Oncologist; 2019 Feb; 24(2):202-210. PubMed ID: 30190302
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real world prospective experience of axitinib in metastatic renal cell carcinoma in a large comprehensive cancer centre.
    Matias M; Le Teuff G; Albiges L; Guida A; Brard C; Bacciarelo G; Loriot Y; Massard C; Lassau N; Fizazi K; Escudier B
    Eur J Cancer; 2017 Jul; 79():185-192. PubMed ID: 28511146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Individualised axitinib regimen for patients with metastatic renal cell carcinoma after treatment with checkpoint inhibitors: a multicentre, single-arm, phase 2 study.
    Ornstein MC; Pal SK; Wood LS; Tomer JM; Hobbs BP; Jia XS; Allman KD; Martin A; Olencki T; Davis NB; Gilligan TD; Mortazavi A; Rathmell WK; Garcia JA; Rini BI
    Lancet Oncol; 2019 Oct; 20(10):1386-1394. PubMed ID: 31427205
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Axitinib, a new therapeutic option in renal cell carcinoma.
    Kessler ER; Bowles DW; Flaig TW; Lam ET; Jimeno A
    Drugs Today (Barc); 2012 Oct; 48(10):633-44. PubMed ID: 23110259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of Neoadjuvant Axitinib Influenced the Efficacy in Patients With Advanced Renal Cell Carcinoma.
    Yamamoto Y; Otori T; Inoue R; Yano S; Hirata H; Matsumoto H; Matsuyama K; Matsuyama H
    J Clin Pharmacol; 2020 Feb; 60(2):256-263. PubMed ID: 31538342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hemodialysis does not impact axitinib exposure: clinical case of a patient with metastatic renal cell carcinoma.
    Thiery-Vuillemin A; Orillard E; Mouillet G; Calcagno F; Devillard N; Bouchet S; Royer B
    Cancer Chemother Pharmacol; 2017 Jun; 79(6):1273-1276. PubMed ID: 28451830
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of axitinib in elderly patients with metastatic renal cell carcinoma.
    Miyake H; Harada K; Ozono S; Fujisawa M
    Med Oncol; 2016 Aug; 33(8):95. PubMed ID: 27444960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical outcomes of second-line treatment following prior targeted therapy in patients with metastatic renal cell carcinoma: a comparison of axitinib and nivolumab.
    Suzuki K; Terakawa T; Furukawa J; Harada K; Hinata N; Nakano Y; Fujisawa M
    Int J Clin Oncol; 2020 Sep; 25(9):1678-1686. PubMed ID: 32488547
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of efficacy and safety among axitinib, sunitinib, and sorafenib as neoadjuvant therapy for renal cell carcinoma: a retrospective study.
    Cai W; Cai B; Zhou J; Chen Y; Zhang J; Huang Y; Xue W; Huang J
    Cancer Commun (Lond); 2019 Oct; 39(1):56. PubMed ID: 31601263
    [No Abstract]   [Full Text] [Related]  

  • 20. The efficacy of axitinib as a first-line treatment for metastatic renal cell carcinoma.
    Kameda T; Takayama T; Sugihara T; Takeshima S; Yamazaki M; Komatsubara M; Kamei J; Fujisaki A; Ando S; Kurokawa S; Fujimura T
    Asia Pac J Clin Oncol; 2020 Aug; 16(4):241-246. PubMed ID: 32129940
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.